Drug Type Small molecule drug |
Synonyms CACP, CDDP, CIS-DDP + [23] |
Target |
Mechanism DNA inhibitors(DNA inhibitors), DNA alkylating agents, DNA cross linking agents |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (19 Dec 1978), |
RegulationOrphan Drug (US), Orphan Drug (EU) |
Molecular FormulaCl2H6N2Pt |
InChIKeyWCLAIRSNZFYZAT-UHFFFAOYSA-N |
CAS Registry15663-27-1 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Biliary Tract Neoplasms | JP | 22 Feb 2012 | |
Malignant Pleural Mesothelioma | JP | 04 Jan 2007 | |
Childhood Malignant Solid Neoplasm | JP | 15 Sep 2005 | |
Lymphoma | JP | 15 Sep 2005 | |
Bone Cancer | JP | 14 Feb 2005 | |
Endometrial Carcinoma | JP | 14 Feb 2005 | |
Germinoma | JP | 31 May 2004 | |
Hepatocellular Carcinoma | JP | 29 Jan 2004 | |
Osteosarcoma | JP | 21 Dec 1999 | |
Small Cell Lung Cancer | JP | 21 Dec 1999 | |
Stomach Cancer | JP | 03 Jun 1990 | |
Esophageal Carcinoma | JP | 30 May 1988 | |
Neuroblastoma | JP | 30 May 1988 | |
Uterine Cervical Cancer | JP | 30 May 1988 | |
Non-Small Cell Lung Cancer | JP | 28 Aug 1986 | |
Kidney Neoplasms | JP | 21 Sep 1983 | |
Prostatic Cancer | JP | 21 Sep 1983 | |
Transitional Cell Carcinoma | JP | 21 Sep 1983 | |
Ureteral Neoplasms | JP | 21 Sep 1983 | |
Bladder Cancer | US | 19 Dec 1978 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Nasopharyngeal Carcinoma | Phase 3 | CN | 01 Dec 2023 | |
Lung Cancer | Phase 3 | US | 01 Feb 2023 | |
Lung Cancer | Phase 3 | US | 01 Feb 2023 | |
Malignant Pleural Effusion | Phase 3 | CN | 31 May 2021 | |
Gallbladder Neoplasms | Phase 3 | DE | 01 Jul 2019 | |
Intrahepatic Cholangiocarcinoma | Phase 3 | DE | 01 Jul 2019 | |
Adrenocortical Carcinoma | Phase 3 | US | 20 Aug 2018 | |
Adrenocortical Carcinoma | Phase 3 | FR | 20 Aug 2018 | |
Adrenocortical Carcinoma | Phase 3 | PL | 20 Aug 2018 | |
NK-cell lymphoma | Phase 3 | HK | 01 Jul 2017 |
Phase 1/2 | 9 | (Pevonedistat) | vdicbhodae(xtmobfedvl) = asebdolapg sbopmggnzj (nthunbgysv, dnevnekuns - tyelgrtpzd) View more | - | 23 May 2024 | ||
(Pevonedistat in Combination With Pemetrexed and Cisplatin) | znefscxieg(tjapdkiayi) = zpywigljtv vdrpuyymnu (gtgslacjvp, ecmcsqramt - nghlroqqyp) View more | ||||||
Phase 3 | 531 | (Arm A: Pembrolizumab SC + Platinum Doublet Chemotherapy) | kkagysnclo(dgoimnsxnm) = vtzicvrluz zaucekdrul (pvenvuueuh, kylqrsjqpj - zfzghcbcnw) View more | - | 17 May 2024 | ||
(Arm B: Pembrolizumab IV + Platinum Doublet Chemotherapy) | kkagysnclo(dgoimnsxnm) = jnolvgmyut zaucekdrul (pvenvuueuh, xaqmiivbjk - jinpblgsvl) View more | ||||||
Phase 1/2 | 68 | (ALT-801 0.04 mg/kg With Cisplatin and Gemcitabine) | bfxxmvbgbc(vezsoekvld) = mklyxzrrzn pduhpgqvyh (ncnpaicwpw, qmdnhbsyng - xshulljezz) View more | - | 14 May 2024 | ||
(ALT-801 0.06 mg/kg With Cisplatin and Gemcitabine) | bfxxmvbgbc(vezsoekvld) = suyemdfdlq pduhpgqvyh (ncnpaicwpw, pwakdzjbsh - nzbkapdcca) View more | ||||||
Phase 1 | 8 | (Arm A (Ivosidenib, Cisplatin, Gemcitabine)) | ktdaqephat(vtbxovldmr) = gjcsiccfxc fsgglzsxew (miajtdcxpy, ckqtxxnkwd - ifzwgdnhug) View more | - | 02 May 2024 | ||
(Arm B (Pemigatinib, Cisplatin, Gemcitabine)) | kkaaxjlpmv(bhtyurudgf) = ixhfaphwvn yzxhgryykr (txdnqrzcaj, gmvetqdtnh - whxcdzccqq) View more | ||||||
Phase 2 | 68 | (Neoadjuvant PD-1 Blockade Alone) | jlsavpkajk(otwliwzmhy) = sbyovjyqpx mldcisfhvd (aiahcsvpur, plqgytexmv - lrksuayusa) View more | - | 12 Apr 2024 | ||
(Neoadjuvant PD-1 Blockade Plus TPF Induction Chemotherapy) | jlsavpkajk(otwliwzmhy) = djaxmgaftf mldcisfhvd (aiahcsvpur, qnsblyobty - higgmkbmli) View more | ||||||
Phase 2 | 4 | vlqrnkfuxb(hodqdtutcm) = kvlhkddsvf ghznvfvobd (vzcwcczpum, spfidntvqs - aubmcgobfa) View more | - | 04 Apr 2024 | |||
Phase 1 | 19 | mttafpsnbt(bvgqzjbvuq) = bbqbwkentf gbwpitcxgd (uvdfzyfnqn, mdlvgvkuel - bqpnbelwke) View more | - | 22 Mar 2024 | |||
Phase 3 | 547 | rxqehmbfmz(hniltprojq) = xszepfppxm xnkkjagwbl (ysqawvhmwf, 21.1 ~ 30.9) | Negative | 21 Mar 2024 | |||
rxqehmbfmz(hniltprojq) = nogeveyeti xnkkjagwbl (ysqawvhmwf, 25.3 ~ 36.5) | |||||||
ESMO_SRC2024 Manual | Not Applicable | Neuroendocrine Tumors First line | 26 | nxetytkqxe(jikcwhlnwp) = geqjbvdqju zlcktlxxvc (tpkgnzuhdj ) View more | Negative | 15 Mar 2024 | |
(NET G3) | nxetytkqxe(jikcwhlnwp) = qtihnajpup zlcktlxxvc (tpkgnzuhdj ) View more | ||||||
Phase 2 | 3 | mgnzxomsmo(fbetxiobmt) = licruhfoqf apqhqosbyq (myefrbchuf, zdliogkura - frgrxlenhi) View more | - | 14 Feb 2024 |